Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice

Kazuhiro Kobuke1, Masayasu Yoneda1*, Shuhei Nakanishi2, Haruya Ohno1, Shusaku Maeda1, Genshi Egusa3

1Department of Molecular and Internal Medicine, Graduate School of Biomedical & Health Sciences, Hiroshima University; 2Department of Metabolism and Endocrinology, Hiroshima Red Cross Hospital & Atomic Bomb Survivors Hospital; and 3Egusa Genshi Clinic, Hiroshima, Japan

Keywords
Basal–bolus treatment, Hypoglycemia, Insulin degludec

*Correspondence
Masayasu Yoneda
Tel.: +81-82-257-5198
Fax: +81-82-255-7360
E-mail address: masayone17@hiroshima-u.ac.jp

J Diabetes Investig 2016; 7: 94–99
doi: 10.1111/jdi.12373

Clinical Trial Registry
UMIN-CTR
UMIN000011037

ABSTRACT
Aims/Introduction: Insulin degludec, a new long-acting insulin analog, showed its better glycemic control and reduced risk of hypoglycemia. This is the first prospective observational study that evaluated the efficacy and safety of insulin degludec in routine clinical practice.

Materials and Methods: Japanese patients with type 1 or type 2 diabetes mellitus receiving basal–bolus insulin therapy were switched their basal insulin to degludec, and prospectively observed over a 24-week course. The Diabetes Therapy-Related Quality of Life questionnaire was administered before and 12 weeks after switching.

Results: The participants were 80 diabetes patients = (type 1, 44; type 2, 36). In the type 1 group, there was no difference in glycated hemoglobin levels between the pre-switching and 24-week measurements (from 62 to 62 mmol/mol, \( P = 0.768 \)), whereas the daily insulin dose (per kg of bodyweight) decreased significantly (basal, from 0.25 to 0.20 U/kg, \( P < 0.001 \); bolus, from 0.40 to 0.37 U/kg, \( P = 0.001 \)). In the type 2 group, glycated hemoglobin levels decreased after switching (from 60 to 58 mmol/mol, \( P = 0.028 \)). In the type 1 group, the frequency of hypoglycemia decreased significantly after switching, but not significantly in the type 2 group. Patient satisfaction with the control of hypoglycemia tended to improve in the type 1 group.

Conclusions: Compared with existing long-acting insulin, degludec can maintain glycemic control at a lower insulin dose and frequency of hypoglycemia in type 1 diabetes, while it can improve glycemic control at an equal insulin dose in type 2 diabetes.

INTRODUCTION
In recent years, a desirable approach to glycemic control might involve targeting satisfactory glycemic control while reducing the risk of hypoglycemia, because hypoglycemia is regarded as the main restricting factor leading to poor adherence to treatment and glycemic control, quality of life, and mortality1–3. In order to achieve this approach, short-acting or long-acting insulin analogs have been introduced, and these induce more physiologically accurate insulin secretion patterns compared with existing insulin preparations. As a result, the selection of appropriate drugs can reduce the risk of hypoglycemia when treating patients who frequently experience hypoglycemic episodes. Regarding long-acting insulin analogs (e.g., insulin detemir and insulin glargine), these treatments are associated with a lower incidence of nocturnal hypoglycemia than existing intermediate type insulin preparations4–7. However, there are cases where neither of these treatments, when administered...
using the daily basal insulin regimen, provides sufficient activity for 24 h, thus necessitating a twice-daily regimen\(^8, 9\).

Accordingly, insulin degludec has been developed as a next-generation, long-acting, soluble insulin analog that provides a longer duration of activity\(^10\). In clinical pharmacological studies, insulin degludec exerted a long-lasting action (>42 h)\(^11\), with a flat and stable insulin profile in the glucose-lowering effect for individual patients\(^12\).

By a phase III clinical study, insulin degludec’s ability to lower blood glucose levels has shown non-inferiority to the control drug in the magnitude of glycated hemoglobin (HbA\(_{1c}\)) reduction\(^13, 14\). However, these phase III studies tested a specific group of patients who were selected according to strict criteria regarding baseline HbA\(_{1c}\), body mass index (BMI) and prior medication period, based on the regulatory authority’s guidelines. Thus, the question arose, whether similar efficacy will be observed when insulin degludec is used during routine clinical practice. Furthermore, the insulin dose in previous studies was adjusted with a target fasting blood glucose level of 3.9–5.0 mmol/L (70–90 mg/dL), and direct application of this dose adjustment method would not be suitable in routine clinical practice.

The present study was thus undertaken to evaluate glycemic control and the incidence of adverse reactions (e.g., serious hypoglycemic episodes) when insulin degludec was used in clinical practice by physicians who specialize in treating diabetes mellitus.

**METHODS**

**Study Design and Procedures**

The study was designed as a multicenter, non-randomized, open-label, observational study involving prospective collection of data from clinical cases. The present study enrolled adult Japanese patients with type 1 diabetes mellitus (type 1) or type 2 diabetes mellitus (type 2) who were receiving outpatient care with the basal–bolus regimen at the Department of Endocrinology and Diabetic Medicine, Hiroshima University Hospital (Hiroshima Japan) or at 14 other medical facilities, between June 2013 and May 2014. The exclusion criteria were pregnancy, women hoping to achieve pregnancy, medication that might aggravate glucose metabolism (e.g., corticosteroid), duration of diabetes treatment less than 12 months and patients in whom degludec treatment was deemed inappropriate by the attending physician.

Basal insulin injection with the basal–bolus regimen was switched to once-daily degludec injection. The dose of basal and bolus insulin before and after switching was determined by the attending physician on an individual basis. Concomitant use of other antidiabetic drugs and unrelated medications was also decided by the attending physician, who suggested modifications if they were deemed necessary.

Bodyweight, HbA\(_{1c}\), insulin dose, use of non-insulin antidiabetic drugs and adverse events were recorded during outpatient clinic visits at the time of switching to degludec, as well as at 4, 12 and 24 weeks after switching. Furthermore, self-monitoring of blood glucose (SMBG) records for preprandial (breakfast, supper) glucose levels were collected for 1 month before each visit.

In addition, the frequency of hypoglycemia during the 1 month before each visit was investigated. Hypoglycemia was defined as any of the following criteria: (i) the presence of symptoms that were alleviated by oral ingestion of carbohydrates, an intramuscular injection of glucagon or an intravenous injection of glucose; and (ii) a blood glucose level less than 3.1 mmol/L (56 mg/dL), regardless of the presence or absence of symptoms\(^15\).

Nocturnal hypoglycemia was defined as hypoglycemia developing between the evening insulin injections and awakening the next morning. Serious hypoglycemia was defined as hypoglycemia accompanied by severe central nervous system symptoms that could not be resolved by the patient and required medical intervention.

The Diabetes Therapy-Related Quality of Life questionnaire\(^16\) was administered at the time of switching to degludec and 12 weeks after switching.

The present study was carried out in accordance with the principles of the Declaration of Helsinki (amended in 2008 at Seoul). Prior review and approval regarding the ethical validity, scientific validity and the appropriateness of its implementation were obtained from the Hiroshima University Epidemiological Study Ethical Committee and the ethical committees of the other participating facilities. All patients provided written informed consent before their enrolment. This study was registered in June 2013 with the University hospital Medical Information Network Clinical Trials Registry (registration no. UMIN000011037).

**Efficacy Measures**

The primary end-point was the change in HbA\(_{1c}\) levels at 24 weeks after switching to degludec. The secondary end-points were changes in bodyweight, insulin dose (bolus, basal and total), mean fasting and pre-supper blood glucose levels, frequency of hypoglycemia, and patient satisfaction after switching to degludec.

**Statistical Analysis**

All data were expressed as either mean ± standard deviation or median (interquartile range). Of the patients registered, only those who were followed until week 24 were included in the analysis. In the statistical analysis (comparison pre- and post-treatment data), the paired t-test was used for continuous variables and the Chi squared-test for discrete variables. In all tests, P-values <0.05 were considered statistically significant.

Analysis of SMBG data was carried out for patients in whom pre-breakfast and pre-supper blood glucose level data were available on at least 5 days of the 1-month period. The analysis evaluated changes in pre-prandial (breakfast and supper)
glucose levels (at 5 points of time) during the pre- and post-switching periods.

The Diabetes Therapy-Related Quality of Life questionnaire data were analyzed for patients who answered all questions, using the method reported by Ishii et al.16. According to the report, we analyzed the total score and the score for each question, with 0–100 points assigned to each of the four quality of life subgroups (full score = 100).

RESULTS
There were 80 patients with diabetes mellitus (38 men and 42 women) included in the study and analyzed. Baseline patient characteristics are summarized in Table 1. A total of 44 patients had type 1 diabetes and 36 patients had type 2 diabetes. Before switching, the frequency of basal insulin injection was twice daily in 24 patients, which included 20 type 1 patients. The basal insulin analog used before switching was insulin glargine in 65 patients and insulin detemir in 15 patients. At the time of switching, the basal insulin dose was reduced in 29 type 1 patients (including 13 patients who received basal insulin twice daily, reduced 0.04 ± 0.03 U/kg of bodyweight) and 12 type 2 patients (including two patients who received basal insulin twice daily, reduced 0.03 ± 0.01 U/kg of bodyweight). In all other patients, the basal insulin dose was unchanged or increased at the time of switching.

In the type 1 group, the dose of oral antidiabetic drugs (OADs) was reduced in two patients, increased in one patient and newly started in two patients during the 24-week observation period. In the type 2 group, the dose of OADs was reduced in five patients, gained in five patients, newly started in two patients and discontinued in two patients (Table S1).

During the 24-week observation period, there was no significant change in HbA1c levels in the type 1 group (62 ± 10 to 62 ± 9 mmol/mol [7.8 ± 0.9 to 7.8 ± 0.8%], P = 0.768), although it did decrease significantly in the type 2 group (60 ± 11 to 58 ± 10 mmol/mol [7.7 ± 1.0 to 7.4 ± 0.9%], P = 0.028; Table 2). No significant change in BMI was observed in either group (Table 2).

Regarding insulin dose, basal, bolus and total insulin doses (units of insulin per kg of bodyweight per day) were significantly lower at 24 weeks after switching in the type 1 group (basal 0.25 ± 0.11 to 0.20 ± 0.08 U/kg/day, P < 0.001; bolus 0.40 ± 0.15 to 0.37 ± 0.14 U/kg/day, P = 0.001; total 0.65 ± 0.21 to 0.57 ± 0.17 U/kg/day, P < 0.001). All insulin doses in the type 2 group remained essentially unchanged during the 24-week period (Table 2).

When the frequency of hypoglycemia was analyzed, the entire type 1 group showed a large reduction in the overall frequency of hypoglycemia and nocturnal hypoglycemia after switching (Table 3). Severe hypoglycemia was observed before switching in one patient with type 1 diabetes, although no instances were observed in this group after switching.

Of the 80 patients, SMBG records were available at five or more points of time for 47 patients (26 men and 21 women; 24 type 1 patients and 23 type 2 patients). In both the type 1 and 2 groups, there was no significant change in the mean of the pre-breakfast or pre-supper blood glucose levels over the 24-week period (Table S2).

Correctly completed questionnaires were collected from 70 patients (34 men and 36 women; 40 type 1 patients and 30

Table 1 | Baseline characteristics of the study participants

| Characteristic          | Overall (n = 80) | Type 1 (n = 44) | Type 2 (n = 36) |
|-------------------------|-----------------|----------------|-----------------|
| Sex (women/men)         | 42/38           | 27/17          | 15/21           |
| Age (years)             | 59.0 ± 13.3     | 58.1 ± 14.3    | 60.0 ± 12.0     |
| Duration of diabetes (years) | 14.8 ± 9.9     | 14.9 ± 10.5    | 14.7 ± 9.3     |
| BMI (kg/m²)             | 22.9 ± 4.3      | 21.7 ± 3.1     | 24.4 ± 5.0     |
| HbA₁c (mmol/mol)        | 61 ± 12         | 62 ± 10        | 60 ± 11        |
| HbA₁c (%)               | 7.7 ± 0.9       | 7.8 ± 0.9      | 7.7 ± 1.0      |
| Fasting serum CPR (nmol/L) | 0.07 (0.03–0.17) | 0.03 (0.03–0.07) | 0.17 (0.11–0.40) |
| Basal insulin Injection twice a day (n) | 24 | 20 | 4 |
| Glargine/Detemir (n)    | 65/15           | 32/12          | 33/3           |
| Patients receiving OADs (n) | 31 | 6 | 25 |

Data are presented as mean ± standard deviation or median (interquartile). BMI, body mass index; CPR, C-peptide reactivity; HbA₁c, glycated hemoglobin; OADs, oral antidiabetic drugs.

Table 2 | Mean changes of glycated hemoglobin, body mass index and the daily insulin dose

| HbA₁c (mmol/mol) | Baseline | 4 weeks | 12 weeks | 24 weeks |
|------------------|----------|---------|----------|----------|
| Type 1 (n = 44)  | 62 ± 10  | 61 ± 10 | 60 ± 10  | 62 ± 9   |
| Type 2 (n = 36)  | 60 ± 11  | 57 ± 13 | 59 ± 11  | 58 ± 10* |
| BMI (kg/m²)      |          |         |          |          |
| Type 1 (n = 44)  | 21.7 ± 3.1 | 21.5 ± 2.7 | 21.4 ± 3.0 | 21.6 ± 2.9 |
| Type 2 (n = 36)  | 24.4 ± 5.0 | 24.2 ± 5.4 | 24.2 ± 5.3 | 24.1 ± 5.2 |
| Daily insulin dose (U/kg of bodyweight) |        |         |          |          |
| Type 1 (n = 44)  | 0.25 ± 0.11 | 0.22 ± 0.09* | 0.20 ± 0.08* | 0.20 ± 0.08* |
| Bolus            | 0.40 ± 0.15 | 0.39 ± 0.14 | 0.38 ± 0.14* | 0.37 ± 0.14* |
| Total            | 0.65 ± 0.21 | 0.61 ± 0.18* | 0.58 ± 0.18* | 0.57 ± 0.17* |
| Type 2 (n = 36)  | 0.20 ± 0.10 | 0.20 ± 0.10 | 0.20 ± 0.10 | 0.20 ± 0.09 |
| Bolus            | 0.30 ± 0.16 | 0.29 ± 0.14 | 0.29 ± 0.16 | 0.28 ± 0.12 |
| Total            | 0.50 ± 0.22 | 0.47 ± 0.19 | 0.49 ± 0.23 | 0.47 ± 0.18 |

Data are presented as mean ± standard deviation. *P < 0.05 by the paired t-test for differences from baseline. BMI, body mass index; HbA₁c, glycated hemoglobin.
type 2 patients). A comparison of the questionnaire results between weeks 0 and 12 showed no significant difference in the overall score for both the type 1 and 2 groups (Table 4). When the questions were divided into four categories, and the answers for each category were compared between weeks 0 and 12, there was no significant difference in the scores for social activity/daily living, anxiety/discomfort with treatment or treatment satisfaction level. However, the scores for hypoglycemia showed a tendency towards increased satisfaction levels in the type 1 group, although this tendency was not statistically significant ($P = 0.06$).

During the 24-week follow-up period, two adverse events were reported. One patient complained of vomiting before the week 4 visit, which appeared to be associated with infectious gastroenteritis and was resolved by outpatient treatment; degludec treatment was subsequently continued. The other patient was hospitalized as a result of a seizure before the week 24 visit. This event appeared to represent a sequela of cerebral infarction (an unrelated event), rather than hypoglycemia. In this case, degludec treatment was discontinued after recovery from the seizure. A direct causal relationship to degludec treatment was not noted in either of these cases.

**DISCUSSION**

In the present study, Japanese patients with type 1 or type 2 diabetes were switched from conventional long-acting basal insulin to insulin degludec, and were observed for 24 weeks during routine clinical care. During the observation period, the type 1 group showed a significant reduction in both insulin dose and the frequency of hypoglycemia, although there was no significant change in HbA1c levels. The type 2 group showed no reduction in insulin dose, but a significant reduction in HbA1c levels.

In a previous phase III clinical study comparing insulin degludec with insulin glargine in a basal–bolus regimen, the degludec group showed a reduced frequency of hypoglycemia, particularly at night, while showing non-inferiority to glargine in its blood glucose-lowering effect. In a subsequent long-term observational study, the basal and total insulin doses were lower in the degludec group compared with the glargine group. There is also a study that found that switching to degludec resulted in lower basal and total insulin dose among patients who had previously received twice-daily basal insulin injections, although that study only involved a small number of patients. Unlike the findings of preceding studies, the present study found a reduction not only in the basal but bolus insulin doses among type 1 diabetic patients. The type 1 group contained a high percentage of patients who were receiving twice-daily basal insulin injections before switching, although the reduction in basal insulin dose after switching did not aggravate their glycemic control. This was likely caused by the long-acting degludec enabling sufficient replenishment of basal insulin through the daily injection.

Among type 2 diabetic patients, a previous phase III study has shown the non-inferiority of degludec compared with glargine, and found that degludec reduced the overall frequency of hypoglycemia and nocturnal hypoglycemia. In the treat-to-target study of degludec and glargine in insulin-therapy-naive patients (with basal supported oral therapy), degludec allowed glycemic control, with a lower frequency of nocturnal hypoglycemia compared with glargine. In the present study, the frequency of hypoglycemia in the type 2

---

| Table 3 | Change of the frequency of hypoglycemic episodes |
|---------|-----------------------------------------------|
|         | **Type 1 (n = 44)** | **Type 2 (n = 36)** |
|         | Overall | Severe | Nocturnal | Overall | Severe | Nocturnal |
| Baseline | Participants | 19 | 1 | 9 | 1 | 0 | 1 |
|          | Episodes  | 81 | 1 | 21 | 1 | 0 | 1 |
|          | Rate†    | 22.09 | 0.27 | 5.72 | 0.33 | 0 | 0.33 |
| 24 weeks | Participants | 17 | 0 | 2 | 0 | 0 | 0 |
|          | Episodes  | 39 | 0 | 3 | 0 | 0 | 0 |
|          | Rate†    | 10.64* | 0 | 0.82* | 1 | 0 | 0 |

†Rate, the rate of hypoglycemic episodes per patient-year of exposure. *P < 0.05 by the paired t-test for differences from baseline. Participants, patients with hypoglycemic episodes.

| Table 4 | Change of the score of Diabetes Therapy-Related Quality of Life questionnaire |
|---------|-----------------------------------------------|
|         | **Baseline** | **12 weeks** | **P-value** |
| Type 1 (n = 40) | | | |
| 1) Burden on social activities and daily activities | 592 ± 21.1 | 606 ± 19.5 | 0.56 |
| 2) Anxiety and dissatisfaction with treatment | 488 ± 21.0 | 514 ± 20.4 | 0.25 |
| 3) Hypoglycemia | 39.7 ± 26.3 | 44.9 ± 26.6 | 0.06 |
| 4) Satisfaction with treatment | 465 ± 16.0 | 466 ± 16.2 | 0.97 |
| Total | 51.9 ± 17.6 | 54.0 ± 17.0 | 0.22 |
| Type 2 (n = 30) | | | |
| 1) Burden on social activities and daily activities | 64.7 ± 23.0 | 623 ± 25.5 | 0.43 |
| 2) Anxiety and dissatisfaction with treatment | 53.5 ± 25.4 | 536 ± 26.2 | 0.99 |
| 3) Hypoglycemia | 58.7 ± 29.9 | 62.7 ± 25.5 | 0.32 |
| 4) Satisfaction with treatment | 59.3 ± 24.2 | 606 ± 21.9 | 0.75 |
| Total | 598 ± 21.0 | 599 ± 21.7 | 0.99 |

Data are presented as mean ± standard deviation.
group was low before switching, and no significant change was detected after switching. In addition, a significant reduction in HbA1c levels was achieved in the type 2 group, as it was possible to maintain the insulin dose because of the low frequency of hypoglycemia.

Regarding quality of life and patient satisfaction with their treatment, a meta-analysis of the data from phase III studies reported an increase in physical and mental scores. In the present study, there was no significant difference in the overall scores, likely because our observation was confined to a short period of time (12 weeks after switching). Our analysis of the hypoglycemic episodes reported by patients, the SMBG data, and the questionnaire results showed that the subjective symptoms of hypoglycemia and related anxiety were alleviated, likely because the long-lasting activity of degludec was effective in reducing hypoglycemia.

The results of the present study are limited by the single-arm, non-controlled design; the small sample size; the exclusively Japanese patient population; and the short observation period (24 weeks). Furthermore, as the use of oral-dose antidiabetics was modified according to the discretion of the attending physicians, we cannot rule out the influence of changing oral medication on the results for type 2 diabetic patients. We are continuing this study, with the survey period extended to 52 weeks, and we plan to carry out further analysis while increasing the number of enrolled patients.

In conclusion, the present study showed that the use of insulin degludec in Japanese patients with type 1 diabetes enabled glycemic control with a significant reduction in both insulin dose and frequency of hypoglycemia. In contrast, in type 2 diabetes, insulin degludec did not change insulin dose and frequency of hypoglycemia, but it did show better glycemic control compared with existing long-acting insulin preparations. As a new basal insulin analog, insulin degludec might provide a useful alternative for diabetic patients who require insulin therapy.

ACKNOWLEDGMENTS
We thank the investigators and trial staff for their participation: Murakami Memorial Hospital, National Hospital Organization Kure Medical Center, Hiroshima City Asa Hospital, Miyoshi Central Hospital, Tenjingawa Nakamura Naika Clinic, Tsuchiya General Hospital, Akioa Hospital, Saijo Central Hospital, Mihara Medical Associations Hospital, Kawamura Naika Clinic, Nojima Naika Clinic, Oda Naika Clinic and Nippon Telegraph and Telephone (NTT) West Corporation Chugoku Health Administration Center. This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

DISCLOSURE
The authors declare no conflict of interest.

REFERENCES
1. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45: 937–948.
2. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–2559.
3. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–2572.
4. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73–82.
5. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129–139.
6. Bartley PC, Bogoev M, Larsen J, et al. A Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25: 442–449.
7. Niskanen L, Virkamäki A, Hansen JB, et al. Fasting plasma glucose variability as a marker of nocturnal hypoglycaemia in diabetes: evidence from the PREDICTIVE study. Diabetes Res Clin Pract 2009; 2: e15–e18.
8. Le Floch JP, Lévy M, Mosnier-Pudar H, et al. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). Diabet Care 2009; 32: 32–37.
9. Dornhorst A, Lüddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract 2007; 61: 523–528.
10. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29: 2104–2114.
11. Hansen BF, Kurtzhals P, Jensen AB, et al. Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 2011; 54: 2226–2231.
12. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859–864.
13. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a randomized, open-label, parallel-group phase 3 study. Diabetologia 2015; 58: 1745–1755.
diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet* 2012; 379: 1489–1497.

14. Garber AJ, King AB, Del Prato S, *et al.* Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. *Lancet* 2012; 379: 1498–1507.

15. American Diabetes Association. Standards of medical care in diabetes—2011. *Diabetes Care* 2011; 34: S11–S16.

16. Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. *J Med Econ* 2012; 15: 556–563.

17. Mathieu C, Hollander P, Miranda-Palma B, *et al.* Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. *J Clin Endocrinol Metab* 2013; 98: 1154–1162.

18. Bode BW, Buse JB, Fisher M, *et al.* Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal–bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial. *Diabet Med* 2013; 30: 1293–1297.

19. Kusunoki Y, Katsuno T, Miyakoshi K, *et al.* Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus. *Diabetes Ther* 2013; 4: 461–472.

20. Zinman B, Philis-Tsimikas A, Cariou B, *et al.* Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). *Diabetes Care* 2012; 35: 2464–2471.

21. Rodbard HW, Cariou B, Zinman B, *et al.* Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. *Diabet Med* 2013; 30: 1298–1304.

22. Freemantle N, Meneghini L, Christensen T, *et al.* Insulin degludec improves health-related quality of life (SF-36®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. *Diabet Med* 2013; 30: 226–232.

**SUPPORTING INFORMATION**

Additional Supporting Information may be found in the online version of this article:

- Table S1 | Change of oral antidiabetic drugs.
- Table S2 | Change of mean self-monitoring of blood glucose profile.